About 15 Trademarks found that are owned by Itm Isotope Technologies Munich Se

Radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing lutetium for treating and diagnosing tumours

The mark consists of the term "ENDOLUCIN" over the term "BETA". A design of an upside-down rain drop with another drop inside appears to the right and above the term "ENDOLUCIN".

Radiopharmaceutical preparations, namely, precursors containing Lutetium for therapeutic or diagnostic purposes; Radioactive substances for medical purposes, namely, for radio-labelling pharmaceutical compounds for use in nuclear medicine

The mark consists of stylized letters "ITM" with two dots coming from the top of the "i" all positioned above the phrase "PASSION FOR PRECISION".

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography (PET) or single photon emission tomography (SPECT), target radionuclide and peptide receptor radionuclide therapy (PRRT); theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumors; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET); radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; radiopharmaceuticals for use with high-sensitivity molecular imaging technologies such as PET (positron emission tomography) or SPECT (single photon emission tomography), for imaging organs and lesions and for early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumor diseases

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope for diagnosis purposes; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases

Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology

Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope for diagnostic purposes; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases

Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology

Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology

The mark consists of "ITM MEDICAL ISOTOPES" in stylized form with two circles emanating from the left corner of the "I" in "ITM" at a diagonal.

Radiopharmaceutical preparations, in particular gallium coordination complexes and gallium DOTATOC for treating and diagnosing tumors

In the statement, line 12, through line 13, "POSITRONS EMISSION STOMATOGRAPHY (PTE), EMISSION STOMATO-GRAPHY" should be deleted, and "POSITRONS EMISSION TOMOGRAPHY (PET), EMISSION TOMOGRAPHY" should be inserted. In the statement, line 26, "NEURORADIOLOGIE" should be deleted, and "NEURORADIOLOGY" should be inserted.

Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations and radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy, diagnostics and therapy of pain, diagnostics and therapy of inflammations, diagnostics and therapy of metabolic disorders, palliative therapy, ablative therapy, [ positrons emission stomatography (PTE), emission stomatography ] * positrons emission tomography (PET), emission tomography * with single photons (SPECT), x-ray diagnostics, gamma spectrometry, nuclear spin tomography, scintigraphy, dosimetry, radiopharmaceutic products, and medical products containing sources for radiation

The mark consists of the wording "SOLUCIN" and an inverted teardrop shape inside of another teardrop shape.